Loading…
Ticagrelor use and practice patterns among Canadian cardiac surgeons
Background and Aim The P2Y12 platelet receptor inhibitor ticagrelor is widely used in patients following acute coronary syndromes or in those who have received coronary stents. Bentracimab is a monoclonal antibody‐based reversal agent that is being formally evaluated in a Phase 3 clinical trial. Her...
Saved in:
| Published in: | Journal of cardiac surgery 2021-08, Vol.36 (8), p.2793-2801 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3426-91ec025255155e2f2f1820af0da970cbae0ce7a6439485f1dac59228319c0c533 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3426-91ec025255155e2f2f1820af0da970cbae0ce7a6439485f1dac59228319c0c533 |
| container_end_page | 2801 |
| container_issue | 8 |
| container_start_page | 2793 |
| container_title | Journal of cardiac surgery |
| container_volume | 36 |
| creator | Makhdoum, Ahmad Dhingra, Nitish K. Kirubaharan, Aathmika Eikelboom, Rachel Luc, Jessica Dagher, Olina Bierer, Joel Cartier, Andreanne Vaillancourt, Olivier Vo, Thin X. Forgie, Keir Bisleri, Gianluigi Yau, Terrence M. Verma, Subodh Yanagawa, Bobby |
| description | Background and Aim
The P2Y12 platelet receptor inhibitor ticagrelor is widely used in patients following acute coronary syndromes or in those who have received coronary stents. Bentracimab is a monoclonal antibody‐based reversal agent that is being formally evaluated in a Phase 3 clinical trial. Here, we probe the knowledge, attitudes, and practice patterns of cardiac surgeons regarding their perioperative management of ticagrelor and potential application of a ticagrelor reversal agent.
Methods
A questionnaire was developed by a working group of cardiac surgeons to inquire into participants’ practices and beliefs regarding ticagrelor and disseminated to practicing, Canadian‐trained cardiac surgeons.
Results
A total of 70 Canadian‐trained cardiac surgeons participated. Bleeding risk was identified as the most significant consideration when surgically revascularizing ticagrelor‐treated patients (90%). There is variability in the duration of withholding ticagrelor before coronary artery bypass graft procedure in a stable patient; 44.3% wait 3 days and 32.9% wait 4 days or longer. Currently, 15.7% of cardiac surgeons prophylactically give platelet transfusions and fresh frozen plasma intraoperatively following protamine infusion in patients who have recently received ticagrelor. Interestingly, 47.1% of surveyed surgeons were aware of a reversal agent for ticagrelor, 91.4% of cardiac surgeons would consider utilizing a ticagrelor reversal agent if available, and 51.4% acknowledged that the introduction of such an agent would be a major advance in clinical practice.
Conclusions
The present survey identified ticagrelor‐related bleeding as a major concern for cardiac surgeons. Surgeons recognized the significant unmet need that a ticagrelor reversal agent would address. |
| doi_str_mv | 10.1111/jocs.15636 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2531534304</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2531534304</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3426-91ec025255155e2f2f1820af0da970cbae0ce7a6439485f1dac59228319c0c533</originalsourceid><addsrcrecordid>eNp9kEtLw0AUhQdRsFY3_oJZipB655UmS4lvCl1Y18N1clNS0kycSZD-e1Pj2rM5m-9eOB9j1wIWYszdzru4ECZV6QmbCaMhyUQuTtkMsixNQGs4Zxcx7gCk1Apm7GFTO9wGanzgQySObcm7gK6vHfEO-55CGznufbvlBbZY1thyh2Fsx-MQtuTbeMnOKmwiXf31nH08PW6Kl2S1fn4t7leJU1qmSS7IgTTSGGEMyUpWIpOAFZSYL8F9IoGjJaZa5TozlSjRmVzKTIncgTNKzdnN9LcL_mug2Nt9HR01Dbbkh2ilUcKocZce0dsJdcHHGKiyXaj3GA5WgD2qskdV9lfVCIsJ_q4bOvxD2rd18T7d_AA_KGsZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2531534304</pqid></control><display><type>article</type><title>Ticagrelor use and practice patterns among Canadian cardiac surgeons</title><source>Wiley</source><creator>Makhdoum, Ahmad ; Dhingra, Nitish K. ; Kirubaharan, Aathmika ; Eikelboom, Rachel ; Luc, Jessica ; Dagher, Olina ; Bierer, Joel ; Cartier, Andreanne ; Vaillancourt, Olivier ; Vo, Thin X. ; Forgie, Keir ; Bisleri, Gianluigi ; Yau, Terrence M. ; Verma, Subodh ; Yanagawa, Bobby</creator><creatorcontrib>Makhdoum, Ahmad ; Dhingra, Nitish K. ; Kirubaharan, Aathmika ; Eikelboom, Rachel ; Luc, Jessica ; Dagher, Olina ; Bierer, Joel ; Cartier, Andreanne ; Vaillancourt, Olivier ; Vo, Thin X. ; Forgie, Keir ; Bisleri, Gianluigi ; Yau, Terrence M. ; Verma, Subodh ; Yanagawa, Bobby</creatorcontrib><description>Background and Aim
The P2Y12 platelet receptor inhibitor ticagrelor is widely used in patients following acute coronary syndromes or in those who have received coronary stents. Bentracimab is a monoclonal antibody‐based reversal agent that is being formally evaluated in a Phase 3 clinical trial. Here, we probe the knowledge, attitudes, and practice patterns of cardiac surgeons regarding their perioperative management of ticagrelor and potential application of a ticagrelor reversal agent.
Methods
A questionnaire was developed by a working group of cardiac surgeons to inquire into participants’ practices and beliefs regarding ticagrelor and disseminated to practicing, Canadian‐trained cardiac surgeons.
Results
A total of 70 Canadian‐trained cardiac surgeons participated. Bleeding risk was identified as the most significant consideration when surgically revascularizing ticagrelor‐treated patients (90%). There is variability in the duration of withholding ticagrelor before coronary artery bypass graft procedure in a stable patient; 44.3% wait 3 days and 32.9% wait 4 days or longer. Currently, 15.7% of cardiac surgeons prophylactically give platelet transfusions and fresh frozen plasma intraoperatively following protamine infusion in patients who have recently received ticagrelor. Interestingly, 47.1% of surveyed surgeons were aware of a reversal agent for ticagrelor, 91.4% of cardiac surgeons would consider utilizing a ticagrelor reversal agent if available, and 51.4% acknowledged that the introduction of such an agent would be a major advance in clinical practice.
Conclusions
The present survey identified ticagrelor‐related bleeding as a major concern for cardiac surgeons. Surgeons recognized the significant unmet need that a ticagrelor reversal agent would address.</description><identifier>ISSN: 0886-0440</identifier><identifier>EISSN: 1540-8191</identifier><identifier>DOI: 10.1111/jocs.15636</identifier><language>eng</language><subject>ACS ; CABG ; survey ; ticagrelor</subject><ispartof>Journal of cardiac surgery, 2021-08, Vol.36 (8), p.2793-2801</ispartof><rights>2021 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3426-91ec025255155e2f2f1820af0da970cbae0ce7a6439485f1dac59228319c0c533</citedby><cites>FETCH-LOGICAL-c3426-91ec025255155e2f2f1820af0da970cbae0ce7a6439485f1dac59228319c0c533</cites><orcidid>0000-0001-7700-5051 ; 0000-0002-3567-3796</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjocs.15636$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjocs.15636$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids></links><search><creatorcontrib>Makhdoum, Ahmad</creatorcontrib><creatorcontrib>Dhingra, Nitish K.</creatorcontrib><creatorcontrib>Kirubaharan, Aathmika</creatorcontrib><creatorcontrib>Eikelboom, Rachel</creatorcontrib><creatorcontrib>Luc, Jessica</creatorcontrib><creatorcontrib>Dagher, Olina</creatorcontrib><creatorcontrib>Bierer, Joel</creatorcontrib><creatorcontrib>Cartier, Andreanne</creatorcontrib><creatorcontrib>Vaillancourt, Olivier</creatorcontrib><creatorcontrib>Vo, Thin X.</creatorcontrib><creatorcontrib>Forgie, Keir</creatorcontrib><creatorcontrib>Bisleri, Gianluigi</creatorcontrib><creatorcontrib>Yau, Terrence M.</creatorcontrib><creatorcontrib>Verma, Subodh</creatorcontrib><creatorcontrib>Yanagawa, Bobby</creatorcontrib><title>Ticagrelor use and practice patterns among Canadian cardiac surgeons</title><title>Journal of cardiac surgery</title><description>Background and Aim
The P2Y12 platelet receptor inhibitor ticagrelor is widely used in patients following acute coronary syndromes or in those who have received coronary stents. Bentracimab is a monoclonal antibody‐based reversal agent that is being formally evaluated in a Phase 3 clinical trial. Here, we probe the knowledge, attitudes, and practice patterns of cardiac surgeons regarding their perioperative management of ticagrelor and potential application of a ticagrelor reversal agent.
Methods
A questionnaire was developed by a working group of cardiac surgeons to inquire into participants’ practices and beliefs regarding ticagrelor and disseminated to practicing, Canadian‐trained cardiac surgeons.
Results
A total of 70 Canadian‐trained cardiac surgeons participated. Bleeding risk was identified as the most significant consideration when surgically revascularizing ticagrelor‐treated patients (90%). There is variability in the duration of withholding ticagrelor before coronary artery bypass graft procedure in a stable patient; 44.3% wait 3 days and 32.9% wait 4 days or longer. Currently, 15.7% of cardiac surgeons prophylactically give platelet transfusions and fresh frozen plasma intraoperatively following protamine infusion in patients who have recently received ticagrelor. Interestingly, 47.1% of surveyed surgeons were aware of a reversal agent for ticagrelor, 91.4% of cardiac surgeons would consider utilizing a ticagrelor reversal agent if available, and 51.4% acknowledged that the introduction of such an agent would be a major advance in clinical practice.
Conclusions
The present survey identified ticagrelor‐related bleeding as a major concern for cardiac surgeons. Surgeons recognized the significant unmet need that a ticagrelor reversal agent would address.</description><subject>ACS</subject><subject>CABG</subject><subject>survey</subject><subject>ticagrelor</subject><issn>0886-0440</issn><issn>1540-8191</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLw0AUhQdRsFY3_oJZipB655UmS4lvCl1Y18N1clNS0kycSZD-e1Pj2rM5m-9eOB9j1wIWYszdzru4ECZV6QmbCaMhyUQuTtkMsixNQGs4Zxcx7gCk1Apm7GFTO9wGanzgQySObcm7gK6vHfEO-55CGznufbvlBbZY1thyh2Fsx-MQtuTbeMnOKmwiXf31nH08PW6Kl2S1fn4t7leJU1qmSS7IgTTSGGEMyUpWIpOAFZSYL8F9IoGjJaZa5TozlSjRmVzKTIncgTNKzdnN9LcL_mug2Nt9HR01Dbbkh2ilUcKocZce0dsJdcHHGKiyXaj3GA5WgD2qskdV9lfVCIsJ_q4bOvxD2rd18T7d_AA_KGsZ</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Makhdoum, Ahmad</creator><creator>Dhingra, Nitish K.</creator><creator>Kirubaharan, Aathmika</creator><creator>Eikelboom, Rachel</creator><creator>Luc, Jessica</creator><creator>Dagher, Olina</creator><creator>Bierer, Joel</creator><creator>Cartier, Andreanne</creator><creator>Vaillancourt, Olivier</creator><creator>Vo, Thin X.</creator><creator>Forgie, Keir</creator><creator>Bisleri, Gianluigi</creator><creator>Yau, Terrence M.</creator><creator>Verma, Subodh</creator><creator>Yanagawa, Bobby</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7700-5051</orcidid><orcidid>https://orcid.org/0000-0002-3567-3796</orcidid></search><sort><creationdate>202108</creationdate><title>Ticagrelor use and practice patterns among Canadian cardiac surgeons</title><author>Makhdoum, Ahmad ; Dhingra, Nitish K. ; Kirubaharan, Aathmika ; Eikelboom, Rachel ; Luc, Jessica ; Dagher, Olina ; Bierer, Joel ; Cartier, Andreanne ; Vaillancourt, Olivier ; Vo, Thin X. ; Forgie, Keir ; Bisleri, Gianluigi ; Yau, Terrence M. ; Verma, Subodh ; Yanagawa, Bobby</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3426-91ec025255155e2f2f1820af0da970cbae0ce7a6439485f1dac59228319c0c533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACS</topic><topic>CABG</topic><topic>survey</topic><topic>ticagrelor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Makhdoum, Ahmad</creatorcontrib><creatorcontrib>Dhingra, Nitish K.</creatorcontrib><creatorcontrib>Kirubaharan, Aathmika</creatorcontrib><creatorcontrib>Eikelboom, Rachel</creatorcontrib><creatorcontrib>Luc, Jessica</creatorcontrib><creatorcontrib>Dagher, Olina</creatorcontrib><creatorcontrib>Bierer, Joel</creatorcontrib><creatorcontrib>Cartier, Andreanne</creatorcontrib><creatorcontrib>Vaillancourt, Olivier</creatorcontrib><creatorcontrib>Vo, Thin X.</creatorcontrib><creatorcontrib>Forgie, Keir</creatorcontrib><creatorcontrib>Bisleri, Gianluigi</creatorcontrib><creatorcontrib>Yau, Terrence M.</creatorcontrib><creatorcontrib>Verma, Subodh</creatorcontrib><creatorcontrib>Yanagawa, Bobby</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiac surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Makhdoum, Ahmad</au><au>Dhingra, Nitish K.</au><au>Kirubaharan, Aathmika</au><au>Eikelboom, Rachel</au><au>Luc, Jessica</au><au>Dagher, Olina</au><au>Bierer, Joel</au><au>Cartier, Andreanne</au><au>Vaillancourt, Olivier</au><au>Vo, Thin X.</au><au>Forgie, Keir</au><au>Bisleri, Gianluigi</au><au>Yau, Terrence M.</au><au>Verma, Subodh</au><au>Yanagawa, Bobby</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ticagrelor use and practice patterns among Canadian cardiac surgeons</atitle><jtitle>Journal of cardiac surgery</jtitle><date>2021-08</date><risdate>2021</risdate><volume>36</volume><issue>8</issue><spage>2793</spage><epage>2801</epage><pages>2793-2801</pages><issn>0886-0440</issn><eissn>1540-8191</eissn><notes>Ahmad Makhdoum and Nitish K. Dhingra are co‐first authors and contributed equally to the study.</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Background and Aim
The P2Y12 platelet receptor inhibitor ticagrelor is widely used in patients following acute coronary syndromes or in those who have received coronary stents. Bentracimab is a monoclonal antibody‐based reversal agent that is being formally evaluated in a Phase 3 clinical trial. Here, we probe the knowledge, attitudes, and practice patterns of cardiac surgeons regarding their perioperative management of ticagrelor and potential application of a ticagrelor reversal agent.
Methods
A questionnaire was developed by a working group of cardiac surgeons to inquire into participants’ practices and beliefs regarding ticagrelor and disseminated to practicing, Canadian‐trained cardiac surgeons.
Results
A total of 70 Canadian‐trained cardiac surgeons participated. Bleeding risk was identified as the most significant consideration when surgically revascularizing ticagrelor‐treated patients (90%). There is variability in the duration of withholding ticagrelor before coronary artery bypass graft procedure in a stable patient; 44.3% wait 3 days and 32.9% wait 4 days or longer. Currently, 15.7% of cardiac surgeons prophylactically give platelet transfusions and fresh frozen plasma intraoperatively following protamine infusion in patients who have recently received ticagrelor. Interestingly, 47.1% of surveyed surgeons were aware of a reversal agent for ticagrelor, 91.4% of cardiac surgeons would consider utilizing a ticagrelor reversal agent if available, and 51.4% acknowledged that the introduction of such an agent would be a major advance in clinical practice.
Conclusions
The present survey identified ticagrelor‐related bleeding as a major concern for cardiac surgeons. Surgeons recognized the significant unmet need that a ticagrelor reversal agent would address.</abstract><doi>10.1111/jocs.15636</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7700-5051</orcidid><orcidid>https://orcid.org/0000-0002-3567-3796</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0886-0440 |
| ispartof | Journal of cardiac surgery, 2021-08, Vol.36 (8), p.2793-2801 |
| issn | 0886-0440 1540-8191 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2531534304 |
| source | Wiley |
| subjects | ACS CABG survey ticagrelor |
| title | Ticagrelor use and practice patterns among Canadian cardiac surgeons |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T21%3A21%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ticagrelor%20use%20and%20practice%20patterns%20among%20Canadian%20cardiac%20surgeons&rft.jtitle=Journal%20of%20cardiac%20surgery&rft.au=Makhdoum,%20Ahmad&rft.date=2021-08&rft.volume=36&rft.issue=8&rft.spage=2793&rft.epage=2801&rft.pages=2793-2801&rft.issn=0886-0440&rft.eissn=1540-8191&rft_id=info:doi/10.1111/jocs.15636&rft_dat=%3Cproquest_cross%3E2531534304%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3426-91ec025255155e2f2f1820af0da970cbae0ce7a6439485f1dac59228319c0c533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2531534304&rft_id=info:pmid/&rfr_iscdi=true |